Bildnachweis: neoplas med, WITENO, neoplas med.
neoplas med GmbH from Greifswald, Germany, is considered a pioneer in medical cold plasma therapy. The company has been setting standards since its foundation in 2009. ‘We are revolutionising the treatment of acute, infected, and chronic wounds with our clinically validated argon jet plasma technology,’ says Ulrike Sailer, CEO of neoplas med.
The main product, kINPen® MED, is the first approved argon cold plasma jet worldwide. The individually controllable ‘plasma effluent’ enables contact-free and customisable therapy directly on the wound. Gold standard studies demonstrate a significantly faster reduction in wound area and a significantly higher number of completely healed wounds within just six weeks of therapy – with lower treatment costs and no known undesirable side effects or resistance development. According to Sailer, kINPen® MED is used in around 75% of university hospitals in Germany, Austria, and Switzerland. Over 500,000 applications have confirmed its clinical safety. With over 400 published studies and MDR certification in 2024, neoplas med has set a global standard.
Growth through research and strong partners
‘Our core competence lies in our unique precision technology and scientific excellence,’ explains Sailer. In addition to CE approval in 2013, its successes include expansion into the Middle East starting in 2022 and the launch of a veterinary product in the US in 2024. According to Sailer, the partnership with Japanese technology group Niterra Co., Ltd. is crucial to the growth story. Niterra has invested a total of USD 25 million since 2022. The current financing round brought in USD 18 million. Dirk Schapeler, President of Niterra Ventures, praises the collaboration: ‘We have been impressed by the convincing positive effects of the argon cold plasma jet kINPen® MED on patients. Further investment was the logical next step.’ The partnership will enable further development of the platform technology and expansion into Europe, the Middle East, and North America. Sailer adds that the investor shares neoplas med’s vision: ‘Together, we want to establish argon jet plasma as a standard therapy and redefine global wound care.’
University and hanseatic city of Greifswald: An ecosystem for innovation
The Greifswald location plays a key role in the company’s success. ‘Our close ties to the Leibniz Institute for Plasma Science and Technology and the University Medical Center Greifswald create ideal conditions,’ says Sailer. At the Z4 Innovation Centre, neoplas med benefits from short distances, intensive exchange, and a researchoriented environment. Martin Nätscher, authorised signatory of the operating company WITENO GmbH, also emphasises the advantages: ‘Greifswald is innovative. Over 70 research institutes and high-tech companies form a strong network.’ Around a third of the population works in research, development, or teaching. The high quality of life and the young population – including 10,000 students – further strengthen the location. Nätscher underlines the fact that Z4 offers unique synergies for plasma technology and life sciences. Flexible laboratory and production space and the proximity to the university campus greatly facilitate the path from research to market maturity. ‘Companies find concentrated expertise and short development cycles here,’ he says. Sailer agrees: ‘Greifswald not only offers us technological excellence, but also an environment in which our team feels comfortable and can grow.’ The high density of researchers in the field of plasma and life sciences makes the city one of Europe’s leading centres. neoplas med sees the location as a decisive competitive advantage. The regional culture of innovation and the strong links between science and industry offer ideal conditions for future growth.
